Skip to main content
. Author manuscript; available in PMC: 2011 May 18.
Published in final edited form as: J Immunol. 2011 Feb 4;186(6):3421–3431. doi: 10.4049/jimmunol.1000569

FIGURE 3.

FIGURE 3

Dynamic investigation of CD226+ NK cells in SLE patients during therapy. PBMCs were isolated from SLE patients during therapy on the indicated days. A, Proportion of NK cells detected in six patients during the exacerbation stage (left panel). Percentage of CD226+ NK cells of total NK cells in the same six patients (right panel). B, Two representative examples (Patient 1 and Patient 4) are shown from six independent patients; CD3−CD56+ cells were gated, and the percentage of CD226+ NK cells was analyzed. C, Proportion of NK cells in nine patients during remission (left panel). Percentage of CD226+ NK cells of total NK cells in the same nine patients (right panel). D, Two representative examples (Patient 1 and Patient 7) are shown from nine independent patients; CD3−CD56+ cells were gated, and the percentage of CD226+ NK cells was analyzed. The dashed vertical lines indicate the proportion of CD226+ NK cells at the end of treatment.